The next wave of cellular immunotherapies in pancreatic cancer

The next wave of cellular immunotherapies in pancreatic cancer.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL:
Journal or Publication Title: Molecular Therapy - Oncolytics
Volume: 24
Page Range: pp. 561-576
Date: 17 March 2022
Divisions: Gene and Stem Cell Therapy
Depositing User: General Admin
Identification Number: 10.1016/j.omto.2022.01.010
ISSN: 23727705
Date Deposited: 26 Sep 2022 00:27

Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes.

Yeo, Dannel
Giardina, Caroline
Saxena, Payal
Rasko, John E.J.
Last Modified: 26 Sep 2022 00:27

Actions (login required)

View Item View Item